NGOtiate er et dansk konsulenthus
Vi er en sjælden hybrid og en pioner inden for vores felt
Om os
NGOtiate er et dansk konsulenthus, der blev grundlagt i 2007. Vi er en sjælden hybrid og en pioner inden for vores felt:
Vores ydelser
be the change
Rådgivning og praktisk hjælp til patientforeninger and digitale communities
- Interessent- og kommunikationsstrategiudvikling samt udvikling af planer for implementering.
- Design af relaterede digitale kommunikations-, marketing- eller fundraising-initiativer
- Daglig support af dig på vej til dit mål
- Viden om, hvordan man samarbejder med forskningsbaserede organisationer for at bane vej for eller støtte medicinudvikling i dit / dine interesseområde samt relateret match-finding
Rådgivning og praktisk hjælp til forskningsbaserede organizationer
- Introduktion til strategisk patientinvolvering og relaterede fordele, praksis, retningslinjer og kritiske succesfaktorer
- Udvikling af patient/brugerinddragelsesstrategier – på virksomhedsniveau, porteføljeniveau eller molekylespecifikt
- Anvendt strategisk patient/brugerinddragelse i forhold til at øge specifik performance, eller den samlede præstation på tværs af værdikæden
- Udvikling af intern infrastruktur for strategisk patient/brugerinddragelse (inklusive eller ekskluderende relateret uddannelse forestået af eksperter i dette)
Sådan er vi anderledes
the partnering paradigm
Disease experience experts (aka ‘patients’) are increasingly involved in medicines R&D, advising on, for example, the design of clinical trials and related strategies, as well as in the development of patient education and support programs.
While truly collaborating with key patient opinion leaders and their communities at the very early stages of medicines R&D is not exactly ‘business as usual’ for pharma, the expectation and ask from the patient communities, however, is crystal clear: Engage us and our communities from the get-go.
This ask is the foundation of e.g. the EUPATI initiative, as well as backed by the regulators in the EU and US, who in 2020 alone issued three new guidance documents to R&D-focused organizations, providing directions on where and how to ensure that key decisions are made and bolstered on primary insights, advice and evidence from patients.
Sources: Eupati.eu, fda.gov and EMA Europe
The value of strategic patient engagement
- Optimizing performance across value chain and ultimately end-user products (ref 1,6)
- Positive effect (e.g. financial effect) on clinical trial recruitment and retention (ref 2,3,4)
- Opportunity for researchers to learn from patients as disease experience experts (ref 6)
- Challenge the set way of thinking – often leading to improved research design, delivery, and dissemination (ref 6)
- Wider impacts of a changed innovation, research culture and agenda (ref 5)
Sources:
1: Wicks P, Richards T, Denegri S, Godlee F. Patients’ roles and rights in research.
2: Crocker Joanna C, Ricci-Cabello Ignacio, Parker Adwoa, Hirst Jennifer A, Chant Alan, Petit-Zeman Sophie et al. Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis
3: Boivin Antoine, Richards Tessa, Forsythe Laura, Grégoire Alexandre, Esperance Audrey, Abelson Julia et al. Evaluating patient and public involvement in research.
4: Levitan, Getz et al. 2018: Assessing the Financial Value of Patient Engagement 5 Staley, K. “Researchers don’t know what they’re missing”—the impact of patient involvement in research
6: Vat et. al (2019) Evaluating the “return on patient engagement initiatives” in medicines research and development
Kom i gang
step 1 - Ræk ud til os
teamET
NGOtiate
Ny Carlsberg Vej 23